Clinical trials: Severe Pneumonia
Covid19
Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection
Multicentre, multinational, non-interventional, observational, retrospective, patient record study to evaluate changes in coagulation parameters in patients with severe COVID-19 infection receiving/not treatment with antithrombin…
- Trial name
- NCT04651400
- Testing
- Antithrombin III
- Where
- 6 sites in Austria, France and 2 more
- Volunteers
- 300 people
- Sponsor
- Octapharma
Complement Deficiency, Antibody Deficiency
Systematic Search for Primary Immunodeficiency in Adults With Infections
Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections …
- Conditions
- Complement Deficiency, Antibody Deficiency, Chronic Sinus Infection, Meningitis, Bacterial
- Trial name
- SPIDAC (NCT02972281)
- Testing
- Immunological diagnosis tests
- Where
- 19 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Lille
Covid19
Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study
This is a multi-center, observational study that will enroll 1) patients with severe COVID-19 who have agreed to undergo therapy with Seraph® 100 under the existing EUA; 2) patients (medical record data) that have been previously…
- Trial name
- PURIFY-OBS-1 (NCT04606498)
- Testing
- Observational
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Covid19, BCG Vaccination Reaction
Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland
Countries that have not carried out universal mass vaccination against tuberculosis (BCG) have been shown to have higher incidence and death rates due to COVID-19 than countries with mass, long-term BCG immunization programmes.
- Conditions
- Covid19, BCG Vaccination Reaction, SARS-CoV Infection
- Trial name
- NCT04648800
- Testing
- BCG-10 vaccine, 0.9% saline
- Where
- 6 sites in Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hanna Czajka
Covid19, SARS-CoV Infection
Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Stress is underpinned by a biological reaction of the organism allowing the production of energy to respond to a change in the environment (or stressor).
- Conditions
- Covid19, SARS-CoV Infection, Burnout, Caregiver, Burnout, Professional
- Trial name
- COVID-TRUST (NCT04517136)
- Testing
- Assessment of work-related stress, Saliva sample collection, Cardiac and electrodermal recordings
- Where
- France
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Mechanical Ventilation Complication, Severe Acute Respiratory Infection
The REDEEM Pilot Study: A Feasibility RCT of Early ECMO in Severe Acute Respiratory Infection, Including COVID-19, WHO
Patients who are critically ill in intensive care with moderate to severe acute respiratory infection often require mechanical ventilation.
- Conditions
- Mechanical Ventilation Complication, Severe Acute Respiratory Infection, Covid19
- Trial name
- REDEEM (NCT04708457)
- Testing
- VV-ECMO
- Where
- 2 sites in Australia, Germany
- Volunteers
- 6 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Sepsis, Severe Community-acquired Pneumonia (sCAP)
Molecular Biomarkers for Sepsis
This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and…
- Conditions
- Sepsis, Severe Community-acquired Pneumonia (sCAP), Infection, Bacterial
- Trial name
- NCT04280354
- Testing
- compare data patterns by data-driven algorithms to determine sepsis, compare data patterns by data-driven algorithms to predict sepsis-related mortality
- Where
- 15 sites in Switzerland
- Volunteers
- 3 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19
This is a randomized, double-blinded, placebo-controlled clinical trial. This study is to evaluate the effectiveness and safety of Yinqiaosan-Maxingganshitang in the treatment of the major symptoms of mild and moderate COVID-19…
- Trial name
- NCT05787327
- Testing
- Chinese Herb
- Where
- Hong Kong
- Volunteers
- 96 people
- Sponsor
- Chinese University of Hong Kong
COVID-19
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
The purpose of the study is to determine if Convalescent anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Methylene Blue Treated (MBT) plasma plus Standard Medical Treatment (SMT) can reduce all-cause mortality…
- Trial name
- NCT04547127
- Testing
- Convalescent anti-SARS-CoV-2 MBT Plasma, Standard Medical Treatment
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Instituto Grifols, S.A.
SARS-CoV-2 Infection
EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Causing COVID19 Disease in Compliance With the World Health Organization (WHO)
Rapid antigen detection (RAD) tests are used to perform rapid diagnosis of SARS-CoV-2 infection based on a qualitative approach.
- Trial name
- WHO (NCT05618561)
- Testing
- EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test
- Where
- 5 sites in Croatia, Greece and 1 more
- Volunteers
- 599 people, healthy volunteers welcome
- Sponsor
- AnteoTech Ltd
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression.
- Trial name
- NCT04389944
- Testing
- convalescent plasma application to SARS-CoV-2 infected patients
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Stroke, Cerebrovascular Accident
Enhancing Plasticity in Stroke Patients With Severe Motor Deficit
This study will evaluate the effectiveness of sustained peripheral nerve stimulation coupled with functional motor training, to improve hand motor function in poorly recovered stroke patients.
- Trial name
- NCT02633215
- Testing
- S88 Dual Output Stimulator by Grass Technologies
- Volunteers
- 36 people
- Sponsor
- Lumy Sawaki
COVID-19, Lung Injury
Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
The primary objective of the study is to evaluate the days until reaching clinical stability after starting randomization in hospitalized patients with elevated inflammatory parameters and severe COVID-19 lung injury.
- Trial name
- TACROVID (NCT04341038)
- Testing
- Tacrolimus, Methylprednisolone
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Hospital Universitari de Bellvitge
Pneumonia, Viral
Toclizumam Versus Dexamethasone in Severe Covid-19 Cases
randomized controlled trial comparing survival benefit of Tocilizumab therapy with dexamethasone in patients with severe COVID 19
- Trial name
- NCT04519385
- Testing
- Tocilizumab, Dexamethasone
- Where
- Egypt
- Volunteers
- 69 people
- Sponsor
- South Valley University
Infection, Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2
Host-pathogen Interactions During SARS-CoV-2 Infection
The new Severe acute respiratory syndrome coronavirus (SARS-CoV-2) named coronavirus disease 2019 (COVID-19) is currently responsible for a pandemic spread of febrile respiratory infections, responsible for a veritable global…
- Trial name
- HPI-COVID-19 (NCT04376476)
- Testing
- Blood sample, Low or upper respiratory tract sample, Stool collection or fecal swab
- Where
- 12 sites in France
- Volunteers
- 140 people
- Sponsor
- Hospices Civils de Lyon
COVID-19
Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial
The clinical trial is designed as a prospective, multi-center, double-blind, randomised, placebo-controlled, interventional trial to assess safety, tolerability and efficacy of Adrecizumab (on top of SOC) in patients with…
- Trial name
- AGNES-19 (NCT05156671)
- Testing
- Adrecizumab (HAM 8101)
- Where
- 13 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
This phase II trial studies how well giving temsirolimus together with cetuximab works compared to temsirolimus alone in treating patients with recurrent and/or metastatic head and neck cancer who did not respond to previous…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- MAESTRO HN (NCT01256385)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, China
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.